WS #10527
Stat News reports that a single 79-year-old patient (likely Trump) received early access to Eli Lilly's experimental obesity drug retatrutide, which could be a major catalyst for LLY if confirmed.
Trump Possibly Receiving Experimental Obesity Drug
Stat News reports that a single 79-year-old patient (likely Trump) received early access to Eli Lilly's experimental obesity drug retatrutide, which could be a major catalyst for LLY if confirmed.